This clinical expert consensus statement reviews the physiologic impact and clinical utility of percutaneous mechanical circulatory support devices in high-risk PCI, cardiogenic shock, and heart failure.
Although historically the intra-aortic balloon pump has been the only mechanical circulatory support device available to clinicians, a number of new devices have become commercially available and have entered clinical practice. These include axial flow pumps, such as Impella(®); left atrial to femoral artery bypass pumps, specifically the TandemHeart; and new devices for institution of extracorporeal membrane oxygenation. These devices differ significantly in their hemodynamic effects, insertion, monitoring, and clinical applicability. This document reviews the physiologic impact on the circulation of these devices and their use in specific clinical situations. These situations include patients undergoing high-risk percutaneous coronary intervention, those presenting with cardiogenic shock, and acute decompensated heart failure. Specialized uses for right-sided support and in pediatric populations are discussed and the clinical utility of mechanical circulatory support devices is reviewed, as are the American College of Cardiology/American Heart Association clinical practice guidelines.
Rihal et al. (Thu,) conducted a review in High-risk percutaneous coronary intervention, cardiogenic shock, and acute decompensated heart failure. Percutaneous mechanical circulatory support devices (Impella, TandemHeart, ECMO, IABP) was evaluated. This clinical expert consensus statement reviews the physiologic impact and clinical utility of percutaneous mechanical circulatory support devices in high-risk PCI, cardiogenic shock, and heart failure.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: